Abbott Laboratories (ABT) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Abbott Laboratories (ABT) insider buying and selling: 5 purchases, 10 sales
60 Form 4 Table I transactions filed with the SEC by Abbott Laboratories insiders between 2025-09-03 and 2026-09-25 (15-month history): 5 open-market purchases and 10 sales, plus 45 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $46.2M by Ford Robert B on 2026-08-25.
Abbott Laboratories insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Abbott Laboratories insiders filed 5 purchases worth $4.4M and 10 sales worth $47.5M on the open market. The net balance is on the sell side: $43.1M more sold than bought.
The biggest buyer was Ford Robert B (CHAIRMAN AND CEO): $2.0M in 1 purchase, out of 4 different buyers. The biggest seller was Ford Robert B (CHAIRMAN AND CEO): $46.2M in 1 sale, out of 7 different sellers.
The largest trade of the period was a sale of $46.2M on Aug 25, 2026, by Ford Robert B (CHAIRMAN AND CEO). Form 4 on sec.gov (0001612571-26-000011).
None of the 10 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 0 purchases and 3 sales, against 3 and 0 in the three before. The latest purchase is from May 7, 2026; the latest sale from Sep 2, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Abbott Laboratories has more sales than 31 of the other 58, ranks 17 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Abbott Laboratories included.
The 20 most important trades
The 5 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 60 ABT trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-01-23 | 2026-01-26 | Ford Robert B | CHAIRMAN AND CEO | $2.0M | P — Open-market purchase Indirect holding, through: Ford Family Trust 2 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.735 to $107.485, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. | SEC |
| 2026-02-04 | 2026-02-06 | Starks Daniel J | Director | $1.1M | P — Open-market purchase2 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.8150 to $109.5204, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.7700 to $108.7150, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | SEC |
| 2026-04-27 | 2026-04-28 | Starks Daniel J | Director | $927k | P — Open-market purchaseForm 4 footnoteF2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.43 to $93.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | SEC |
| 2026-04-23 | 2026-04-27 | Boudreau Philip P | EVP AND CFO | $201k | P — Open-market purchase Indirect holding, through: By Spouse | SEC |
| 2026-05-07 | 2026-06-18 | Stratton John G | Director | $174k | P — Open-market purchase | SEC |
| 2026-08-25 | 2026-08-27 | Ford Robert B | CHAIRMAN AND CEO | $46.2M | S — Open-market sale2 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | SEC |
| 2026-08-11 | 2026-08-13 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | $643k | S — Open-market sale | SEC |
| 2025-11-25 | 2025-11-25 | Shroff Eric | Senior Vice President | $203k | S — Open-market saleForm 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.02 to $128.06, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | SEC |
| 2026-03-02 | 2026-03-03 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | $132k | S — Open-market sale | SEC |
| 2026-03-02 | 2026-03-03 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | $102k | S — Open-market sale | SEC |
| 2026-03-02 | 2026-03-03 | Shroff Eric | Senior Vice President | $82k | S — Open-market sale | SEC |
| 2026-03-02 | 2026-03-03 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | $71k | S — Open-market sale | SEC |
| 2026-03-02 | 2026-03-03 | Mccoy John A. Jr. | VICE PRESIDENT AND CONTROLLER | $68k | S — Open-market sale | SEC |
| 2026-03-02 | 2026-03-03 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | $30k | S — Open-market sale | SEC |
| 2026-09-02 | 2026-09-03 | Mccoy John A. Jr. | VICE PRESIDENT AND CONTROLLER | $3k | S — Open-market sale | SEC |
| 2026-08-25 | 2026-08-27 | Ford Robert B | CHAIRMAN AND CEO | $21.5M | M — Option exercise | SEC |
| 2026-09-23 | 2026-09-25 | Conroy Kevin T | Director | $5.5M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-03 | Ford Robert B | CHAIRMAN AND CEO | $3.5M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-03 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | $997k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-03 | Boudreau Philip P | EVP AND CFO | $865k | F — Tax withholding (shares surrendered for taxes) | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 3, 2025 and Sep 25, 2026, Abbott Laboratories open-market activity adds up to 5 purchases worth $4.4M and 10 sales worth $47.5M. The net balance is $43.1M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Abbott Laboratories's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 23 | $0 |
| F | Tax withholding (shares surrendered for taxes) | 17 | $13.9M |
| S | Open-market sale | 10 | $47.5M |
| P | Open-market purchase | 5 | $4.4M |
| I | Discretionary transaction in a plan | 3 | $1.3M |
| G | Gift | 1 | $189k |
| M | Option exercise | 1 | $21.5M |
| Total | Everything filed in the period | 60 | $88.9M |
23 of the 60 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 23 distinct people or entities have filed Abbott Laboratories transactions: 4 bought on the open market and 7 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 7 who sold on the open market (10 sales in all), the three biggest sellers account for $47.3M of the $47.5M: 99% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Ford Robert B | CHAIRMAN AND CEO | 5 | $2.0M (1) | $46.2M (1) | 2026-08-27 |
| Starks Daniel J | Director | 3 | $2.0M (2) | — | 2026-04-28 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | 6 | — | $775k (2) | 2026-08-13 |
| Shroff Eric | Senior Vice President | 4 | — | $285k (2) | 2026-03-03 |
| Boudreau Philip P | EVP AND CFO | 6 | $201k (1) | — | 2026-09-03 |
| Stratton John G | Director | 2 | $174k (1) | — | 2026-06-18 |
| Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | 4 | — | $102k (1) | 2026-03-03 |
| Moreland Mary K | EXECUTIVE VICE PRESIDENT | 4 | — | $71k (1) | 2026-04-29 |
Shown here are the 8 who moved the most money, out of 23. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Mar 2026: 0 purchases and 6 sales, worth $485k. 7 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 1 | $203k |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 1 | $2.0M | 0 | $0 |
| Feb 2026 | 1 | $1.1M | 0 | $0 |
| Mar 2026 | 0 | $0 | 6 | $485k |
| Apr 2026 | 2 | $1.1M | 0 | $0 |
| May 2026 | 1 | $174k | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 2 | $46.8M |
| Sep 2026 | 0 | $0 | 1 | $3k |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Abbott Laboratories (ABT) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 10 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Abbott Laboratories's 5 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Sep 25, 2026, and a Form 4 arrives up to two business days after the trade.
5 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.